379 related articles for article (PubMed ID: 27321283)
1. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.
Chen W; Dai G; Qian Y; Wen L; He X; Liu H; Gao Y; Tang X; Dong B
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751411
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo.
Zhao Y; Zhao X; Chen V; Feng Y; Wang L; Croniger C; Conlon RA; Markowitz S; Fearon E; Puchowicz M; Brunengraber H; Hao Y; Wang Z
Sci Rep; 2019 Dec; 9(1):19180. PubMed ID: 31844152
[TBL] [Abstract][Full Text] [Related]
4. 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against
Zhao Y; Feng X; Chen Y; Selfridge JE; Gorityala S; Du Z; Wang JM; Hao Y; Cioffi G; Conlon RA; Barnholtz-Sloan JS; Saltzman J; Krishnamurthi SS; Vinayak S; Veigl M; Xu Y; Bajor DL; Markowitz SD; Meropol NJ; Eads JR; Wang Z
Cancer Res; 2020 Nov; 80(21):4815-4827. PubMed ID: 32907836
[No Abstract] [Full Text] [Related]
5. Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in
Miller SA; Policastro RA; Savant SS; Sriramkumar S; Ding N; Lu X; Mohammad HP; Cao S; Kalin JH; Cole PA; Zentner GE; O'Hagan HM
Mol Cancer Res; 2020 Feb; 18(2):264-277. PubMed ID: 31704733
[TBL] [Abstract][Full Text] [Related]
6. Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Khan N; Jajeh F; Eberhardt EL; Miller DD; Albrecht DM; Van Doorn R; Hruby MD; Maresh ME; Clipson L; Mukhtar H; Halberg RB
Int J Cancer; 2019 Dec; 145(11):3022-3032. PubMed ID: 31018249
[TBL] [Abstract][Full Text] [Related]
7. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
8. Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.
Zumwalt TJ; Wodarz D; Komarova NL; Toden S; Turner J; Cardenas J; Burn J; Chan AT; Boland CR; Goel A
Cancer Prev Res (Phila); 2017 Mar; 10(3):208-218. PubMed ID: 28154202
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.
Bäumer N; Rehkämper J; Appel N; Terheyden L; Hartmann W; Wardelmann E; Buchholz F; Müller-Tidow C; Berdel WE; Bäumer S
PLoS One; 2018; 13(7):e0200163. PubMed ID: 30001368
[TBL] [Abstract][Full Text] [Related]
11. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
12. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
[TBL] [Abstract][Full Text] [Related]
13. Targeting glutamine metabolism in
Feng X; Hao Y; Wang Z
Genes Dis; 2016 Dec; 3(4):241-243. PubMed ID: 30258894
[TBL] [Abstract][Full Text] [Related]
14. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
Ehrenschwender M; Bittner S; Seibold K; Wajant H
Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
[TBL] [Abstract][Full Text] [Related]
15. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
[TBL] [Abstract][Full Text] [Related]
17. Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels Y; Diaz LA; Schmidt-Kittler O; Cummins JM; Delong L; Cheong I; Rago C; Huso DL; Lengauer C; Kinzler KW; Vogelstein B; Velculescu VE
Cancer Cell; 2005 Jun; 7(6):561-73. PubMed ID: 15950905
[TBL] [Abstract][Full Text] [Related]
18. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
Wang Y; Tang Q; Li M; Jiang S; Wang X
Biochem Biophys Res Commun; 2014 Feb; 444(2):199-204. PubMed ID: 24440701
[TBL] [Abstract][Full Text] [Related]
20. Knockin of mutant PIK3CA activates multiple oncogenic pathways.
Gustin JP; Karakas B; Weiss MB; Abukhdeir AM; Lauring J; Garay JP; Cosgrove D; Tamaki A; Konishi H; Konishi Y; Mohseni M; Wang G; Rosen DM; Denmeade SR; Higgins MJ; Vitolo MI; Bachman KE; Park BH
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2835-40. PubMed ID: 19196980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]